OncoSil Medical Ltd (ASX:OSL, OTC:OCMLF) has secured US Food and Drug Administration (FDA) approval for its OncoSil™ targeted radiation device to treat distal cholangiocarcinoma (dCCA), giving the ...
The Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway aligns CMS and FDA evidence in advance to reduce review times.
Dublin, Sept. 23, 2025 (GLOBE NEWSWIRE) -- The "FDA (Food and Drug Administration) Approval Process for Medical Devices Training Course (Dec 2nd-3rd, 2025)" has been added to ResearchAndMarkets.com's ...
Traditionally, the Food & Drug Administration’s (“FDA”) premarket review of medical devices assumes devices are static. A product is ...
At the upcoming MD&M East show in New York City in May, Janet Kwiatkowski, MBA, MSRA, president and CEO of MAE Group, will give a talk entitled “Importance of Early Dialog & Interaction with the FDA.” ...
The DCGI announces plans for intensifying audits of medical device manufacturing facilities and eliminating test license ...
Most device makers' evidence wasn't built for that. Enlil's four-layer architecture grounds AI in a unified system of record, so every AI-assisted answer and agent action traces back to controlled ...
AI Medical Device Security now hinges on post-market monitoring, SBOM discipline, model drift controls, and clear update ...
The regulation of medical devices in the US has grown increasingly complex, with multiple pathways to gain marketplace entry and a shift toward collecting evidence in the postmarket setting. The ...
An accelerated regulatory pathway in Mexico has positioned the country as a priority launch market for medical devices. Guerreschi: This pathway is designed to reduce approval timelines by the Federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results